Memantine Canon, 20 mg 30 pcs
Out of stock
(E-mail when Stock is available)
Concussion and other brain injuries, Alcoholism, Stroke sequelae, Alzheimer’s disease, Attention and memory disorders, Acquired dementiaModerate to severe Alzheimer’s dementia.
How to take, the dosage
Therapy should be supervised by a physician experienced in the diagnosis and treatment of dementia in Alzheimer’s disease. Therapy should be initiated if the patient (or the patient’s usual caregiver) is willing to monitor the medication regularly.
Levodopa, dopamine receptor agonists and m-cholinoblockers. Simultaneous use of memantine with levodopa drugs, dopamine receptor antagonists, m-cholinoblockers may increase the effect of the latter, as well as with other NMDA-receptor antagonists.
It is recommended to use with caution in patients with epilepsy, history of seizures or in patients with predisposition to epilepsy.
- Hypersensitivity to the active ingredient or any of the ingredients;
- Severe hepatic impairment (Child-Pugh class C);
- Hypersensitivity to the active substance or any of the ingredients of the drug
- Pregnancy Congenital galactose intolerance, lactose deficiency, or impaired glucose/galactose absorption syndrome;
- Breast-feeding period;
- Childhood under 18 years (effectiveness and safety not established).
- Epilepsy, seizure syndrome in history;
- Myocardial infarction in history;
- Heart failure (NYHA class III-IV);
- Uncontrolled arterial hypertension;
- Concurrent use of NMDA receptor antagonists (amantadine, ketamine, dextromethorphan);
- Factors that increase urinary pH (sudden change in diet (switch from meat to vegetarian), heavy intake of alkaline gastric buffers, renal tubular acidosis or severe urinary tract infections caused by Proteus spp.);
- Renal failure;
- Hepatic failure.
Below are the adverse reactions from both studies and spontaneous reports.
WHO classification of the incidence of adverse reactions: Very common (≥1/10); common (≥1/100, < 1/10); infrequent (≥1/1000, < 1/100); rare (≥1/10000, < 1/1000); very rare (< 1/10000),
In the ongoing clinical studies and post-marketing study of Memantine Canon, limited information has been received about overdoses.
Symptoms: In sufficiently large overdoses (200 mg once or more than 100 mg per day for 3 days) the following symptoms have been identified: weakness, fatigue, diarrhea, or no symptoms. In overdose of less than 140 mg or in unknown overdose, the following adverse events have been identified from the nervous system: confusion, drowsiness, dizziness, agitation, aggression, hallucinations and gait disturbance and from the gastrointestinal tract: vomiting and diarrhea.
In the most serious cases of overdose, the patient survived after taking more than 2000 mg of memantine with adverse nervous system events (coma for 10 days, diplopia, agitation). The patient received symptomatic therapy and plasmapheresis and recovered without any sequelae.
The other case of a serious overdose described was 400 mg once. The patient recovered without consequences. Nervous system reactions were noted: anxiety, psychosis, visual hallucinations, stupor, drowsiness, unconsciousness.
Treatment: in case of overdose symptomatic treatment is necessary. There is no specific antidote for memantine intoxication. Standard procedures for evacuation of the drug by irrigation, the use of activated charcoal, forced diuresis, means of alkalizing the urine should be carried out.
If symptoms of central nervous system overexcitation occur, symptomatic therapy should be selected with extreme care.
Acathinol Memantine, Noogeron, Maruksa, Memanthal, Memaneirin, Memantine
Kanonfarma Production ZAO, Russia
Kanonfarma Production ZAO
Buy Memantine Canon, 20 mg 30 pcs with delivery to USA, UK, Europe and over 120 other countries.